A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
News|Videos|September 15, 2026
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
Author(s)Dr. Julia Rotow, Kaitlyn M. Le
Fact checked by: Spencer Feldman
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Advertisement
Advertisement
Dr. Julia Rotow, a thoracic medical oncologist at Dana-Farber Cancer Institute and global co-lead investigator of DESTINY-Lung04, discussed how the trial could change treatment sequencing for patients with newly diagnosed advanced or metastatic HER2-mutant lung cancer.
Related to this article
Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.
A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Advertisement
Advertisement